Alerts will be sent to your verified email
Verify EmailINDOCO
|
Indoco Remedies
|
Novartis
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
54.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
32.0 . | n/a | n/a |
|
Domestic Sales Growth - YoY
|
4.0 % | -5.28 % | n/a |
|
US DMF Filings
|
26.0 . | n/a | n/a |
|
Global DMFs filed
|
147.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.7 % | n/a | 2.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
8.94 % | 8.0 % | 6.83 % |
|
5yr average Equity Multiplier
|
1.9 | 2.72 | 1.3 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.18 | 0.62 |
|
5yr Avg Net Profit Margin
|
5.41 % | 17.12 % | 8.7 % |
|
Price to Book
|
2.06 | 2.55 | 1.61 |
|
P/E
|
0.0 | 18.57 | 16.61 |
|
5yr Avg Cash Conversion Cycle
|
35.3 Days | -23.33 Days | 186.56 Days |
|
Inventory Days
|
70.6 Days | 44.27 Days | 54.35 Days |
|
Days Receivable
|
83.16 Days | 38.18 Days | 189.93 Days |
|
Days Payable
|
111.01 Days | 124.28 Days | 75.78 Days |
|
5yr Average Interest Coverage Ratio
|
7.53 | 65.43 | 14.68 |
|
5yr Avg ROCE
|
13.6 % | 5.91 % | 13.27 % |
|
5yr Avg Operating Profit Margin
|
14.97 % | 15.15 % | 17.03 % |
|
5 yr average Debt to Equity
|
0.49 | 0.0 | 0.11 |
|
5yr CAGR Net Profit
|
n/a | 37.01 % | 4.24 % |
|
5yr Average Return on Assets
|
5.31 % | 3.13 % | 5.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
58.9 % | 70.68 % | 35.39 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.21 % | 0.0 | 0.84 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.31 % | 0.0 | 0.0 |
|
Indoco Remedies
|
Novartis
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|